Package 59572-711-01

{"route": ["SUBCUTANEOUS"], "spl_id": "769ec39a-61bd-4726-b14a-9594897baa67", "openfda": {"nui": ["N0000194025", "N0000009319"], "unii": ["AQK7UBA1LS"], "spl_set_id": ["82f4d266-3f52-41eb-86ba-0abf3cf468e8"], "pharm_class_pe": ["Increased Erythroid Cell Production [PE]"], "pharm_class_epc": ["Erythroid Maturation Agent [EPC]"], "manufacturer_name": ["Celgene Corporation"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, GLASS in 1 CARTON (59572-711-01)  / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS", "package_ndc": "59572-711-01", "marketing_start_date": "20191108"}], "brand_name": "Reblozyl", "product_id": "59572-711_769ec39a-61bd-4726-b14a-9594897baa67", "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION", "pharm_class": ["Erythroid Maturation Agent [EPC]", "Increased Erythroid Cell Production [PE]"], "product_ndc": "59572-711", "generic_name": "Luspatercept", "labeler_name": "Celgene Corporation", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Reblozyl", "active_ingredients": [{"name": "LUSPATERCEPT", "strength": "25 mg/1"}], "application_number": "BLA761136", "marketing_category": "BLA", "marketing_start_date": "20191108", "listing_expiration_date": "20271231"}